



## Reply to Dubbert and von Büнау, “A Probiotic Friend”

 Jean-Philippe Nougayrède,<sup>a</sup>  Eric Oswald<sup>a</sup>

<sup>a</sup>IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France

We read with great interest the comment letter to the editor by Dubbert and von Büнау (1) from Ardeypharm regarding our work, recently published in *mSphere*, on the production of the genotoxin colibactin by the Nissle 1917 probiotic (2). We fully understand and acknowledge the strong commitment made by Ardeypharm—which markets Nissle 1917 under the trade name Mutaflor—with regard to the safety of its customers and the improvement of patient health.

In their letter (1), the authors question our results on the *in vitro* and *in vivo* genotoxicity of Nissle 1917 (2) with respect to their previous publication in which they stated that this *E. coli* strain did not exert such genotoxicity in standard tests (3). These standard tests, which are recommended by the FDA and the OECD, are suitable for testing the mutagenic effect of chemicals on human health. However, we continue to believe that the tests used by the authors are not the most suitable for testing the mutagenic effect of the Nissle 1917 bacteria. The first test they used is an Ames mutation reversion test in *Salmonella*, exposed to a supernatant of Nissle 1917 (3). However, no genotoxic activity associated with colibactin could be observed in the supernatant (4). It is also well-known that *Salmonella* is killed by the siderophore microcins produced by Nissle 1917 (5). These microcins are responsible for the antagonistic activity of Nissle 1917 at the heart of its probiotic property, which is linked to the production of colibactin (6, 7). Although Dubbert and von Büнау write in their letter that all the appropriate controls were performed and that bacterial lawns were observed on the control plates, no quantitative data pertaining to these important controls is mentioned in the publication. The reader therefore has no way of assessing whether the microcin activity of Nissle 1917 generated a false-negative result or not. We agree with the authors that it is important to also test the contact-dependent mutagenic activity of Nissle 1917. Dubbert et al. used a second modified Ames test in which an antibiotic was added so as to inhibit the growth of Nissle 1917, but not that of *Salmonella* (3). However, it is known that inhibiting growth with an antibiotic impairs the production of colibactin (4). Without using a purified and stable form of colibactin, it is impossible to use the Ames test. We therefore maintain that these Ames tests could not work to test the mutagenicity of Nissle 1917 bacteria. Similarly, the Ames test could not demonstrate the mutagenicity of *Helicobacter pylori* (8), which is a well-recognized oncomicrobe.

We agree with the authors that it is crucial to test *in vivo* the genotoxicity of Nissle 1917. We observed histone H2AX phosphorylation (in response to DNA damage) in 8-day-old mice or in axenic mice which had been monocolonized with Nissle 1917, but not with a mutant unable to produce colibactin (2), which is similar to the results reported in young rats or monoxenic mice colonized with other *pks*<sup>+</sup> *E. coli* strains (9, 10). Dubbert et al. reported a contradictory result in another Nissle 1917 genotoxicity test in rats where no detectable DNA damage was demonstrated by a standard comet assay (3). This comet assay allows for the detection of DNA breaks inflicted by colibactin at very high doses, as observed in cells exposed to a very high number of *pks*<sup>+</sup> *E. coli* (4). We now know that these lesions are derived from the generation of DNA interstand cross-links (ICLs) by colibactin, which can break by way of

**Copyright** © 2021 Nougayrède and Oswald.  
This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to  
Jean-Philippe Nougayrède,  
Jean-Philippe.Nougayrede@inrae.fr.

The authors declare no conflict of interest.

This is a response to a letter by Dubbert and von Büнау <https://doi.org/10.1128/mSphere.00856-21>.

**Published** 22 December 2021

depurination and, consequently, generate DNA breaks (11, 12). However, at a more moderate dose of colibactin, ICL lesions remain in the majority, and the comet assay remains negative because ICLs inhibit DNA electrophoretic migration (13). Accordingly, it is quite possible that the negative result the authors obtained arises from the low sensitivity of the comet assay to colibactin-induced DNA damage at a realistic dose *in vivo*.

We agree with the authors that murine tests are not an adequate representation of the use of Nissle 1917 in humans, which exhibit in particular normal or, on the contrary, dysbiotic microbiota and altered barrier functions in inflammatory bowel disease patients. However, the recent detection of the colibactin mutational signature in colorectal tumor banks indicates that colibactin produced by *pks*<sup>+</sup> *E. coli* is indeed produced, and genotoxic, in humans (14, 15). We agree with Dubbert and von Büнау who stated in their letter (1) that these *pks*<sup>+</sup> *E. coli* bacteria are frequently found in young children. Previous work has shown that *pks*<sup>+</sup> *E. coli* induces DNA damage during the perinatal colonization phase in a rat model, with persistent changes to the intestinal tissue homeostasis and cell turnover (10). In addition, the mutational signature of colibactin has also been observed in the intestinal crypts of healthy young humans (16), suggesting that colibactin can imprint damage during childhood, thus leading to potential long-term consequences (17).

The detection of the colibactin mutational signature in colorectal tumors, the understanding of the mechanism of DNA damage, mutagenesis, and transformation, as well as various epidemiological studies showing more *E. coli pks*<sup>+</sup> in colorectal cancer (CRC) patients and finally the experimental reproduction of colibactin-aggravated CRC in mouse models all concur to implicate colibactin in this type of cancer (18). However, we agree with Dubbert and von Büнау (1) that CRC is a multifactorial disease and that other risk factors—in particular, diet—are very important. The authors submit that the mutational signature of colibactin is found in only 5% of the analyzed tissues. Indeed, this signature was identified in 5.3% of the mutations in the adenomatous polyposis coli (APC) gene, mutated in colorectal tumors (14). However, care should be taken not to minimize and misinterpret this figure. First, the colibactin-specific mutation in the APC gene suggests a causal role in CRC. Second, although a significant fraction of driver mutations is induced by other mutagenic processes (including endogenous), a tumor typically harbors between 2 and 10 driver mutations, which can be induced by various environmental genotoxins such as colibactin. This may be sufficient to induce full malignancy (19). The colibactin mutational signature is found in genes other than APC, and another study identifies it in nearly 10% of CRCs (15). In addition, colibactin has been shown to also induce large-scale DNA damage and chromosome instability, which can result in nonspecific mutations and cell transformation (18, 20, 21). Consequently, colibactin may be responsible for inducing a larger fraction of cancers than the fraction of mutations attributed to colibactin in the APC gene.

We again fully agree with Dubbert and von Büнау (1) that CRC is multifactorial, diet and intestinal inflammation contributing in a major way. Indeed, we have shown that food contaminants may participate in conjunction with colibactin to the mutagenesis process (22). As observed by the authors, intestinal inflammation is a well-known factor in CRC, and promotes colibactin expression by *pks*<sup>+</sup> *E. coli* and tumorigenesis (9, 23). It is clear that Nissle 1917 has interesting properties with regard to reducing intestinal inflammation, but to the best of our knowledge, no study has yet thoroughly examined whether its use was associated with a decreased or increased risk of developing colorectal cancer. On the other hand, certain molecules with real potential—such as mesalamine—decrease both inflammation and the production of colibactin by *pks*<sup>+</sup> *E. coli*, and therefore reduce the risk of CRC (24, 25).

In conclusion, the impact of colibactin in cancer can still be discussed and needs to be further studied. However, in light of our results (2) and of the arguments presented

above, it would seem sensible to reevaluate the use of colibactin-producing *E. coli* for therapeutic use in humans.

## REFERENCES

- Dubbert S, von Büнау R. 2021. A probiotic friend. *mSphere* 6:e00856-21. <https://doi.org/10.1128/mSphere.00856-21>.
- Nougayrède J-P, Chagneau CV, Motta J-P, Bossuet-Greif N, Belloy M, Taieb F, Gratadoux J-J, Thomas M, Langella P, Oswald E. 2021. A toxic friend: genotoxic and mutagenic activity of the probiotic strain *Escherichia coli* Nissle 1917. *mSphere* 6:e00624-21. <https://doi.org/10.1128/mSphere.00624-21>.
- Dubbert S, Klinkert B, Schimiczek M, Wassenaar TM, von Büнау R. 2020. No genotoxicity is detectable for *Escherichia coli* strain Nissle 1917 by standard in vitro and in vivo tests. *Eur J Microbiol Immunol* 10:11–19. <https://doi.org/10.1556/1886.2019.00025>.
- Nougayrède J-P, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. 2006. *Escherichia coli* induces DNA double-strand breaks in eukaryotic cells. *Science* 313:848–851. <https://doi.org/10.1126/science.1127059>.
- Sassone-Corsi M, Nuccio S-P, Liu H, Hernandez D, Vu CT, Takahashi AA, Edwards RA, Raffatellu M. 2016. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. *Nature* 540:280–283. <https://doi.org/10.1038/nature20557>.
- Olier M, Marcq I, Salvador-Cartier C, Secher T, Dobrindt U, Boury M, Bacquié V, Pénary M, Gaultier E, Nougayrède J-P, Fioramonti J, Oswald E. 2012. Genotoxicity of *Escherichia coli* Nissle 1917 strain cannot be dissociated from its probiotic activity. *Gut Microbes* 3:501–509. <https://doi.org/10.4161/gmic.21737>.
- Massip C, Branchu P, Bossuet-Greif N, Chagneau CV, Gaillard D, Martin P, Boury M, Sécher T, Dubois D, Nougayrède J-P, Oswald E. 2019. Deciphering the interplay between the genotoxic and probiotic activities of *Escherichia coli* Nissle 1917. *PLoS Pathog* 15:e1008029. <https://doi.org/10.1371/journal.ppat.1008029>.
- Kaneko T, Kawakami Y, Akaimatsu T, Kiyosawa K, Katsuyama T. 2000. Mutagenicity of *Helicobacter pylori* in the Ames test using *Salmonella typhimurium* TA100. *J Int Med Res* 28:222–228. <https://doi.org/10.1177/147323000002800504>.
- Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338:120–123. <https://doi.org/10.1126/science.1224820>.
- Payros D, Secher T, Boury M, Brehin C, Ménard S, Salvador-Cartier C, Cuevas-Ramos G, Watrin C, Marcq I, Nougayrède J-P, Dubois D, Bedu A, Garnier F, Clermont O, Denamur E, Plaisancié P, Theodorou V, Fioramonti J, Olier M, Oswald E. 2014. Maternally acquired genotoxic *Escherichia coli* alters offspring's intestinal homeostasis. *Gut Microbes* 5:313–325. <https://doi.org/10.4161/gmic.28932>.
- Bossuet-Greif N, Vignard J, Taieb F, Mirey G, Dubois D, Petit C, Oswald E, Nougayrède J-P. 2018. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. *mBio* 9:e02393-17. <https://doi.org/10.1128/mBio.02393-17>.
- Xue M, Werneke KM, Herzon SB. 2020. Depurination of colibactin-derived interstrand cross-links. *Biochemistry* 59:892–900. <https://doi.org/10.1021/acs.biochem.9b01070>.
- Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD, Engelward BP, Garrett WS, Balbo S, Balskus EP. 2019. The human gut bacterial genotoxin colibactin alkylates DNA. *Science* 363:eaar7785. <https://doi.org/10.1126/science.aar7785>.
- Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, Miao Y, van der Linden R, van der Elst S, Genomics England Research Consortium, Garcia KC, Top J, Willems RJL, Giannakis M, Bonnet R, Quirke P, Meyerson M, Cuppen E, van Boxtel R, Clevers H. 2020. Mutational signature in colorectal cancer caused by genotoxic pks+ *E. coli*. *Nature* 580:269–273. <https://doi.org/10.1038/s41586-020-2080-8>.
- Dziubańska-Kusibab PJ, Berger H, Battistini F, Bouwman BAM, Iftekhar A, Katainen R, Cajuso T, Crosetto N, Orozco M, Aaltonen LA, Meyer TF. 2020. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer. *Nat Med* 26:1063–1069. <https://doi.org/10.1038/s41591-020-0908-2>.
- Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, Georgakopoulos N, Torrente F, Noorani A, Goddard M, Robinson P, Coorens THH, O'Neill L, Alder C, Wang J, Fitzgerald RC, Zillbauer M, Coleman N, Saeb-Parsy K, Martincorena I, Campbell PJ, Stratton MR. 2019. The landscape of somatic mutation in normal colorectal epithelial cells. *Nature* 574:532–537. <https://doi.org/10.1038/s41586-019-1672-7>.
- Secher T, Brehin C, Oswald E. 2016. Early settlers: which *E. coli* strains do you not want at birth? *Am J Physiol Gastrointest Liver Physiol* 311:G123–G129. <https://doi.org/10.1152/ajpgi.00091.2016>.
- Berger H, Meyer TF. 2021. Mechanistic dissection unmasks colibactin as a prevalent mutagenic driver of cancer. *Cancer Cell* 39:1439–1441. <https://doi.org/10.1016/j.ccell.2021.10.010>.
- Rosendahl Huber A, Van Hoeck A, Van Boxtel R. 2021. The mutagenic impact of environmental exposures in human cells and cancer: imprints through time. *Front Genet* 12:760039. <https://doi.org/10.3389/fgene.2021.760039>.
- Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède J-P. 2010. *Escherichia coli* induces DNA damage in vivo and triggers genomic instability in mammalian cells. *Proc Natl Acad Sci U S A* 107:11537–11542. <https://doi.org/10.1073/pnas.1001261107>.
- Iftekhar A, Berger H, Bouznad N, Heuberger J, Boccellato F, Dobrindt U, Hermeking H, Sigal M, Meyer TF. 2021. Genomic aberrations after short-term exposure to colibactin-producing *E. coli* transform primary colon epithelial cells. *Nat Commun* 12:1003. <https://doi.org/10.1038/s41467-021-21162-y>.
- Payros D, Dobrindt U, Martin P, Secher T, Bracarense APFL, Boury M, Laffitte J, Pinton P, Oswald E, Oswald IP. 2017. The food contaminant deoxynivalenol exacerbates the genotoxicity of gut microbiota. *mBio* 8:e00007-17. <https://doi.org/10.1128/mBio.00007-17>.
- Yang Y, Gharaibeh RZ, Newsome RC, Jobin C. 2020. Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. *Nat Cancer* 1:723–734. <https://doi.org/10.1038/s43018-020-0078-7>.
- Tang-Fichaux M, Chagneau CV, Bossuet-Greif N, Nougayrède J-P, Oswald É, Branchu P. 2020. The polyphosphate kinase of *Escherichia coli* is required for full production of the genotoxin colibactin. *mSphere* 5:e01195-20. <https://doi.org/10.1128/mSphere.01195-20>.
- Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. 2017. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 45:1179–1192. <https://doi.org/10.1111/apt.14023>.